ON THE QUESTION OF THE DEVELOPMENT OF FETAL CONGENITAL MALFORMATIONS IN THE CONDITIONS OF PREVENTIVE USE BY MOTHERS OF FOLIC ACID IN THE PERINATAL PERIOD
Abstract
Neural tube defect relates to congenital defects caused by folic acid deficiency or violation of its exchange. Prophylactic administration of folic acid by pregnant women has greatly reduce the incidence of these malformations. However, despite preventive measures, reports of such serious adverse events continue to be recorded. The analysis showed that one of the possible causes of malformations may be the presence of the polymorphism of the gene encoding 5, 10-methylenetetrahydrofolate. The effect of this mutation on the metabolism of folic acid and possible recommendations to patients are discussed.
About the Authors
I. A. Toropova
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
R. N. Alyautdin
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. S. Alyautdina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
B. K. Romanov
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Thaler CJ. Folate мetabolism and human reproduction. Geburtshilfe Frauenheilkd. 74(9): 845-851.
2. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113.
3. Kang SS, Zhou J, Wong PW, et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988;43:414–421.
4. McAndrew PE, Brandt JT, Pearl DK, et al. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res. 1996;83:195–198.
5. Verhoeff BJ, Tri p MD, Prins MH, et al. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis. 1998;141:161–166.
6. Harmon DL, Woodside JV, Yarnell JW, et al. The common thermolabile variant of methylene tetrahydrofolate reductase is a major determin ant of mild hyperhomocystein aemia. QJM. 1996;89:571–577.
7. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93:7–9.
8. Ströhle A, Wolters M, Hahn A. Nährstoffsupplemente – Möglichkeiten und Grenzen. Teil 2: Ausgewählte Risikogruppen – Supplemente in der Schwangerschaft. Med Mon atsschr Pharm. 2013;36:252–266.
9. Nelen WL, Blom HJ, Thomas CM, et al. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr. 1998;128:1336–1341.
10. Hibbard BM, Hibbard ED, Jeffcoate TN. Folic acid and reproduction. Acta Obstet. Gynecol. Scand. 1965, 44, 375–400.
11. Smithells RW. Multivitamins for the prevention of neural tube defects. How convincing is the evidence? Drugs. 1989;38:849–854.
12. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet. 1991;338:131–137.
13. Wagner C. Biochemical role of folate in cellular metabolism. In: Bailey LB, ed. Folate in health and disease. New York, NY: Marcel Dekker, 1995:23– 42.
14. Chan arin I. The megaloblastic an aemias. London, United Kingdom: Blackwell, 1969;786 – 829.
15. McPartlin J, Halligan A, Scott JM, Darling M, Weir DG. Accelerated folate breakdown in pregn ancy. Lancet 1993;341:148 –9.
16. Fleming AF. Urin ary excretion of folate in pregn ancy. J Obstet Gyn aecol Br Comm 1972;79:916 –20.
17. Tamura T., Picciano M. Folate and human reproduction. Am.J.Clin. Nutr., 2006;83:993–1016.
18. Baymuradova SM, Bitsadze VO, Marov SV, et al. The role of anti phospholi pid syndrome and genetic thrombophilia in the pathogenesis of toxaemia. Tromboz, gemostaz i reologiya. 2002. № 4. Р. 69 (in Russian).
19. Van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ Mutated methylene- tetrahydrofolate reductase as a risk factor for spin a bifida. Lancet 1995, 346, 1070–1071.
20. Holmes V. Homocysteine Is Lower in the Third Trimester of Pregn ancy in Women with Enhanced Folate Status from Continued Folic Acid Supplementation. Clin. Chem. 2005, 51, 629-634.
21. Park SB, Georgiades A. Changes in body composition predict homocysteine changes and hyperhomocysteinemia in Korea.J Korean Med Sci. 2013.7:1015-20.
Review
For citations:
Toropova I.A., Alyautdin R.N., Alyautdina O.S., Romanov B.K. ON THE QUESTION OF THE DEVELOPMENT OF FETAL CONGENITAL MALFORMATIONS IN THE CONDITIONS OF PREVENTIVE USE BY MOTHERS OF FOLIC ACID IN THE PERINATAL PERIOD. Safety and Risk of Pharmacotherapy. 2015;(1):13-20. (In Russ.)
Views:
1170
Email this article 